Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...

Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (TEAEs) being mild or moderate in severity, and the ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...

The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis ...

Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...

Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...

COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...

The net proceeds from these warrant exercises, along with the net proceeds of approximately $141 million from the recent public offering that closed on February 20, 2026, and its existing cash and ...

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

Feb 17 () - ‌Drug ‌developer Compass ​Pathways said on ‌Tuesday ⁠its ⁠psilocybin-based ​depression ​therapy ​met ‌the main ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 ...